Granisetron Injection
- Packing: 3 Ml Vial
- Available Strength : 1 Mg/Ml
Description
Product Description: Our Granisetron Injection is a meticulously formulated pharmaceutical solution crafted to effectively manage nausea and vomiting. It contains granisetron, a selective serotonin 5-HT3 receptor antagonist renowned for its potent antiemetic properties. Manufactured to stringent quality standards, this injection is trusted by healthcare professionals for its reliability and efficacy in preventing and treating nausea and vomiting associated with chemotherapy and radiation therapy.
Indications and Usage: Granisetron Injection is indicated for the prevention and treatment of nausea and vomiting induced by chemotherapy, radiotherapy, and postoperative recovery. It is particularly effective in managing acute and delayed chemotherapy-induced nausea and vomiting in cancer patients undergoing chemotherapy regimens with moderate to high emetogenic potential.
Dosage and Administration: The dosage of Granisetron Injection varies depending on the patient's age, weight, and the emetogenic potential of the chemotherapy regimen or radiation therapy. It is typically administered via intravenous infusion or intramuscular injection under the supervision of a qualified healthcare professional. Dosage adjustments may be necessary based on the patient's response to therapy and individual tolerance.
Dosage Forms and Strengths: Granisetron Injection is available as a sterile solution in vials containing specific concentrations of granisetron formulated for parenteral administration. Each vial is carefully manufactured to ensure accurate dosing and optimal therapeutic outcomes.
Contraindications: This product is contraindicated in patients with a known hypersensitivity to granisetron or any of the excipients. It should not be used in patients with a history of concurrent use of drugs that prolong the QT interval. Additionally, it is contraindicated in patients with severe hepatic impairment.
Warnings and Precautions: Healthcare providers should exercise caution when prescribing Granisetron Injection to patients with a history of cardiac arrhythmias, electrolyte imbalances, or hepatic impairment. Prolonged QT interval and torsades de pointes have been reported with the use of granisetron, especially in patients with preexisting risk factors. Patients should be monitored closely for signs of QT prolongation during therapy.
Adverse Reactions/Side Effects: Common adverse reactions associated with Granisetron Injection include headache, constipation, diarrhea, and dizziness. Rarely, serious adverse effects such as serotonin syndrome, extrapyramidal reactions, and allergic reactions may occur. Patients should be advised to report any unusual symptoms promptly.
Drug Interactions: Concomitant use of Granisetron Injection with other drugs that affect serotonin levels or prolong the QT interval may increase the risk of adverse effects or potentiate the effects of granisetron. Healthcare providers should review the patient's medication profile carefully to avoid potential drug interactions.
Use In Specific Populations Description: Safety and efficacy of Granisetron Injection in pediatric patients, pregnant women, and nursing mothers have not been established conclusively. Healthcare providers should assess the potential risks and benefits before prescribing this medication in these populations.
How Supplied/Storage and Handling: Granisetron Injection is supplied as a sterile solution in vials for parenteral administration. It should be stored at controlled room temperature away from light and moisture. Care should be taken to avoid freezing or excessive heat exposure. Unused portions should be discarded according to standard procedures for biohazardous waste.